News
02-03-2011, 11:40 PM
Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.
More... (http://www.news-medical.net/news/20110204/US-Patent-Office-issues-Notice-of-Allowance-to-Antigen-Express-AE37-cancer-vaccine.aspx)
More... (http://www.news-medical.net/news/20110204/US-Patent-Office-issues-Notice-of-Allowance-to-Antigen-Express-AE37-cancer-vaccine.aspx)